Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression

Open access

Abstract

BACKGROUND: Tumor associated fibroblasts (TAF), are essential for tumor progression providing both a functional and structural supportive environment. TAF, known as activated fibroblasts, have an established biological impact on tumorigenesis as matrix synthesizing or matrix degrading cells, contractile cells, and even blood vessel associated cells. The production of growth factors, cytokines, chemokines, matrix-degrading enzymes, and immunomodulatory mechanisms by these cells augment tumor progression by providing a suitable environment. There are several suggested origins of the TAF including tissue-resident, circulating, and epithelial-to-mesenchymal-transitioned cells. METHODOLOGY/PRINCIPAL FINDINGS: We provide evidence that TAF are derived from mesenchymal stem cells (MSC) that acquire a TAF phenotype following exposure to or systemic recruitment into adenocarcinoma xenograft models including breast, pancreatic, and ovarian. We define the MSC derived TAF in a xenograft ovarian carcinoma model by the immunohistochemical presence of 1) fibroblast specific protein and fibroblast activated protein; 2) markers phenotypically associated with aggressiveness, including tenascin-c, thrombospondin-1, and stromelysin-1; 3) production of pro-tumorigenic growth factors including hepatocyte growth factor, epidermal growth factor, and interleukin-6; and 4) factors indicative of vascularization, including alpha-smooth muscle actin, desmin, and vascular endothelial growth factor. We demonstrate that under long-term tumor conditioning in vitro, MSC express TAF-like proteins. Additionally, human MSC but not murine MSC stimulated tumor growth primarily through the paracrine production of secreted IL6. CONCLUSIONS/SIGNIFICANCE: Our results suggest the dependence of in vitro Skov-3 tumor cell proliferation is due to the presence of tumor-stimulated MSC secreted IL6. The subsequent TAF phenotype arises from the MSC which ultimately promotes tumor growth through the contribution of microvascularization, stromal networks, and the production of tumor-stimulating paracrine factors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0004992

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 In admixtures of tumor and MSC, MSC exhibit four attributes of TAF. (A) Initially, MSC do not express all TAF markers. As shown by western, huMSC, prior to Skov-3 tumor exposure, express low levels of α-SMA, FAP and desmin and are negative for the expression of, FSP, TSP-1, and Tn-C. Following 16 days exposure to Skov-3-conditioned medium, the MSC express Tn-C, TSP-1, FSP and increase expression of α-SMA, FAP and desmsin. (B) The TAF is a fibroblastic cell that has four defining characteristics, which together, distinguish it from the normal fibroblast: The fibroblastic nature of the cell (red; Fibroblast activation protein and fibroblast specific protein); the aggressive/invasive nature of the cell defined by the secreted proteins (green; TSP-1, Tn-C and SL1); the vascularization potential of the cell (blue; α-SMA, desmin and VEGF); and the growth factors secreted by the cell to aid in tumor growth and development (yellow; EGF, HGF, IL-6 and bFGF).
Figure 1 In admixtures of tumor and MSC, MSC exhibit four attributes of TAF. (A) Initially, MSC do not express all TAF markers. As shown by western, huMSC, prior to Skov-3 tumor exposure, express low levels of α-SMA, FAP and desmin and are negative for the expression of, FSP, TSP-1, and Tn-C. Following 16 days exposure to Skov-3-conditioned medium, the MSC express Tn-C, TSP-1, FSP and increase expression of α-SMA, FAP and desmsin. (B) The TAF is a fibroblastic cell that has four defining characteristics, which together, distinguish it from the normal fibroblast: The fibroblastic nature of the cell (red; Fibroblast activation protein and fibroblast specific protein); the aggressive/invasive nature of the cell defined by the secreted proteins (green; TSP-1, Tn-C and SL1); the vascularization potential of the cell (blue; α-SMA, desmin and VEGF); and the growth factors secreted by the cell to aid in tumor growth and development (yellow; EGF, HGF, IL-6 and bFGF).CC BY · PubMed Central
Figure 2 Admixed Skov-3/MSC xenografts express fibroblast markers and invasive markers indicative of TAF. IHC staining for markers that define fibroblast presence are visible in the Skov-3/MSC (1∶1) admixed xenografts but not in Skov-3-only xenografts. Fibroblast markers FAP (A) and FSP (B) are both present throughout the admixed tumors. The three tissue remodeling proteins Tn-C (C), TSP-1 (D) and SL-1 (E) are detectable within the admixed tumors. These two categories cover the first two characteristics of a TAF, and are observed only in tumors exposed to MSC. Human-specific, mouse non-cross-reactive antibodies allow identification of the human MSC-contributory components within the tumor microenvironment.
Figure 2 Admixed Skov-3/MSC xenografts express fibroblast markers and invasive markers indicative of TAF. IHC staining for markers that define fibroblast presence are visible in the Skov-3/MSC (1∶1) admixed xenografts but not in Skov-3-only xenografts. Fibroblast markers FAP (A) and FSP (B) are both present throughout the admixed tumors. The three tissue remodeling proteins Tn-C (C), TSP-1 (D) and SL-1 (E) are detectable within the admixed tumors. These two categories cover the first two characteristics of a TAF, and are observed only in tumors exposed to MSC. Human-specific, mouse non-cross-reactive antibodies allow identification of the human MSC-contributory components within the tumor microenvironment.CC BY · PubMed Central
Figure 3 Admixed Skov-3/MSC xenografts express provascularization markers. One characteristic of the TAF is their ability to form fibrovascular networks, which include vessels and the architectural foundation in which they lay. IHC staining reveals structural proteins α-SMA (A) and desmin (B) as well as factors suggestive of tumor vascularization, including VEGF (C) in the presence of admixed MSC but not in tumors that received no MSC (far right panel). HGF (D) is found within the stromal compartment of the tumor. A strong delineation separating the tumor and stromal compartments is formed when the admixed xenograft is stained for HGF. Likewise, EGF (E) is highly expressed in the stromal regions of the admixed Skov-3 tumor. (F) IL-6 staining is expressed in the Skov-3 alone tumors, however the expression is increased in the admixed tumors.
Figure 3 Admixed Skov-3/MSC xenografts express provascularization markers. One characteristic of the TAF is their ability to form fibrovascular networks, which include vessels and the architectural foundation in which they lay. IHC staining reveals structural proteins α-SMA (A) and desmin (B) as well as factors suggestive of tumor vascularization, including VEGF (C) in the presence of admixed MSC but not in tumors that received no MSC (far right panel). HGF (D) is found within the stromal compartment of the tumor. A strong delineation separating the tumor and stromal compartments is formed when the admixed xenograft is stained for HGF. Likewise, EGF (E) is highly expressed in the stromal regions of the admixed Skov-3 tumor. (F) IL-6 staining is expressed in the Skov-3 alone tumors, however the expression is increased in the admixed tumors.CC BY · PubMed Central
Figure 4 huMSC secreted growth factors promote growth of Skov-3 tumors. The TAF phenotype includes secretion of pro-tumorigenic growth factors. (A) Supported by the secretion of growth factors by the huMSC. In vivo growth of xenograft Skov-3 tumors steadily progress but when mixed at a 1∶1 ratio with MSC rapid growth ensued after day 65. At day 91, the Skov-3/MSC 50/50 tumors were significantly larger than the Skov-3 alone (P<0.05). (B) Skov-3 tumor cell growth is species dependent. The Skov-3 ovarian tumor cells were growth in co-culture with huMSC, and several muMSC including cells isolated from balb/c and C57 mice, and a fibroblast cell line, 3T3. Growth is graphed as fold change relative to normal Skov-3 proliferation. The only cell line that produced adequate factors to induce cell growth is the huMSC (red circles). The huMSC induced Skov-3 growth significantly (P<0.01) better than the other cell lines. (C) Naïve MSC produce basal levels of IL-6, TGF-β, VEGF and HGF. All secreted factors with the exception of HGF are significantly increased upon stimulation with Skov-3 CM (P<0.001).
Figure 4 huMSC secreted growth factors promote growth of Skov-3 tumors. The TAF phenotype includes secretion of pro-tumorigenic growth factors. (A) Supported by the secretion of growth factors by the huMSC. In vivo growth of xenograft Skov-3 tumors steadily progress but when mixed at a 1∶1 ratio with MSC rapid growth ensued after day 65. At day 91, the Skov-3/MSC 50/50 tumors were significantly larger than the Skov-3 alone (P<0.05). (B) Skov-3 tumor cell growth is species dependent. The Skov-3 ovarian tumor cells were growth in co-culture with huMSC, and several muMSC including cells isolated from balb/c and C57 mice, and a fibroblast cell line, 3T3. Growth is graphed as fold change relative to normal Skov-3 proliferation. The only cell line that produced adequate factors to induce cell growth is the huMSC (red circles). The huMSC induced Skov-3 growth significantly (P<0.01) better than the other cell lines. (C) Naïve MSC produce basal levels of IL-6, TGF-β, VEGF and HGF. All secreted factors with the exception of HGF are significantly increased upon stimulation with Skov-3 CM (P<0.001).CC BY · PubMed Central
Figure 5 Growth factors are critical to Skov-3 tumor progression. (A) An in vitro 3D tumor growth assay (TGA) at day 8. Briefly, RFP-labeled Skov-3 tumor cells were mixed with huMSC cells, huMSC conditioned media (CM) or various recombinant cytokines (FGF, HGF, TGF-β, VEGF, EGF, IL-6) in a 3D assays (as described in the materials and methods). EGF (P<0.05) and IL6 (P<0.01) significantly increased the proliferation of Skov-3 cells compared to the Skov-3 only, but less than the MSC (P<0.01) induced Skov-3 proliferation. (B) Immunoprecipitation of IL-6 from the Skov-3/MSC co-culture medium over an 8 day period reveals significantly reduced growth of the Skov-3 (P<0.01) cells as compared with the Skov-3/MSCco-culture. Cell growth is graphed as fold change relative to normal Skov-3 proliferation.
Figure 5 Growth factors are critical to Skov-3 tumor progression. (A) An in vitro 3D tumor growth assay (TGA) at day 8. Briefly, RFP-labeled Skov-3 tumor cells were mixed with huMSC cells, huMSC conditioned media (CM) or various recombinant cytokines (FGF, HGF, TGF-β, VEGF, EGF, IL-6) in a 3D assays (as described in the materials and methods). EGF (P<0.05) and IL6 (P<0.01) significantly increased the proliferation of Skov-3 cells compared to the Skov-3 only, but less than the MSC (P<0.01) induced Skov-3 proliferation. (B) Immunoprecipitation of IL-6 from the Skov-3/MSC co-culture medium over an 8 day period reveals significantly reduced growth of the Skov-3 (P<0.01) cells as compared with the Skov-3/MSCco-culture. Cell growth is graphed as fold change relative to normal Skov-3 proliferation.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 56 references

Research works printed but not linked: 1

  1. M Studeny, 2001, Bone marrow derived mesenchymal stem cells serve as precursors for stromal fibroblasts in malignant tumors and show potential for cancer therapy., Blood, 98

Cited by

See all 891

Metadata

Authors
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Abigail Wexner Research Institute (US)
Corresponding author
Marini, Frank
Venue
PLoS ONE
Published
2009-04-07
Volume
4
Issue
4
Pages
e4992
ISSN
1932-6203 (ISSN-L)
OpenAlex
W1979704965
Cited by
807
References
56
Citations by year
2026: 18 · 2025: 14 · 2024: 29 · 2023: 41 · 2022: 26 · 2021: 48 · 2020: 50 · 2019: 47 · 2018: 43 · 2017: 40 · 2016: 60 · 2015: 59 · 2014: 66 · 2013: 69 · 2012: 71
FWCI
32.78
Type
journal article
Language
en
Open access
Locations
  • PLoS ONE (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Figshare (submittedVersion, cc-by)
Funders
  • U.S. Department of Defense
  • Susan G. Komen for the Cure
  • National Cancer Institute (P50CA116199, CA-16672, CA-55164, R01CA109451, P01CA049639, 16672, P01CA055164, Ca-116199, RC1CA146381, BC083397, CA109451, P30CA016672, CA 49639)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
Keywords
mesenchymal stem cells, cancer-associated fibroblasts, tumor progression, ovarian carcinoma, breast adenocarcinoma, pancreatic ductal adenocarcinoma, paracrine signaling, interleukin-6, microvascularization, tumor microenvironment, SKOV3 cells, xenograft models
MeSH terms
Animals, Cell Division, Female, Fibroblasts, Humans, Ovarian Neoplasms, Transplantation, Heterologous, Disease Progression, Cell Lineage, Mesenchymal Stem Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression. https://app.cochat.ai/papers/10.1371/journal.pone.0004992
The paper
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009). Mesenchymal Stem Cell Transition to Tumor-Associated Fibroblasts Contributes to Fibrovascular Network Expansion and Tumor Progression. PLoS ONE. https://doi.org/10.1371/journal.pone.0004992

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.